ARVN (Arvinas, Inc.) Stock Financials & Earnings | Market Cap Arena

ARVN (Arvinas, Inc.) Stock Financials & Earnings | Market Cap Arena

ARVNArvinas, Inc.

Mkt Cap$907M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$263M

Net Income (TTM)-$81M

EPS (TTM)-$1.22

Free Cash Flow (TTM)-$276M

Gross Margin99.5%

Op. Margin-44.0%

Net Margin-30.8%

FCF Margin-105.0%

P/S Ratio (TTM)3.5x

P/E Ratio (TTM)—

YoY Rev Growth-0.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$33M	$31M	-$88M
Q2 23	$55M	$53M	-$75M
Q3 23	$35M	$33M	-$74M
Q4 23	-$43M	-$45M	-$165M
Q1 24	$25M	$24M	-$83M
Q2 24	$77M	$75M	-$49M
Q3 24	$102M	$102M	-$60M
Q4 24	$59M	$59M	-$58M
Q1 25	$189M	$189M	$71M
Q2 25	$22M	$22M	-$72M
Q3 25	$42M	$42M	-$44M
Q4 25	$10M	$8M	-$72M

Valuation

Quarter	P/S	P/E
Q1 23	6.6x	—
Q2 23	5.7x	—
Q3 23	5.7x	—
Q4 23	11.6x	—
Q1 24	12.7x	—
Q2 24	9.7x	—
Q3 24	5.6x	—
Q4 24	3.4x	—
Q1 25	2.1x	—
Q2 25	2.4x	—
Q3 25	2.9x	—
Q4 25	3.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$91M	-$92M
Q2 23	-$89M	-$89M
Q3 23	-$85M	-$86M
Q4 23	-$83M	-$83M
Q1 24	-$98M	-$98M
Q2 24	$50M	$50M
Q3 24	-$128M	-$129M
Q4 24	-$84M	-$84M
Q1 25	-$89M	-$89M
Q2 25	-$95M	-$97M
Q3 25	-$59M	-$59M
Q4 25	-$30M	-$31M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$1M
Q2 23	$600K
Q3 23	$1M
Q4 23	$100K
Q1 24	$100K
Q2 24	$700K
Q3 24	$700K
Q4 24	$300K
Q1 25	$400K
Q2 25	$1M
Q3 25	$100K
Q4 25	$200K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+22.6%	+42.8%
Q2 23	+61.2%	+29.6%
Q3 23	+4.2%	+11.3%
Q4 23	-213.4%	+7.8%
Q1 24	-22.2%	-9.7%
Q2 24	+40.4%	-3.2%
Q3 24	+196.0%	+50.0%
Q4 24	+237.4%	-3.9%
Q1 25	+646.2%	+8.1%
Q2 25	-70.7%	-24.9%
Q3 25	-59.1%	-47.3%
Q4 25	-84.0%	-30.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$20M	61.2%
Q2 23	$0	0.0%
Q3 23	$17M	48.3%
Q4 23	$17M	—
Q1 24	$19M	73.5%
Q2 24	$22M	28.2%
Q3 24	$25M	24.1%
Q4 24	$23M	39.4%
Q1 25	$15M	7.9%
Q2 25	$10M	46.0%
Q3 25	$0	0.0%
Q4 25	$9M	89.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$95M	—	$23M
Q2 23	$103M	—	$24M
Q3 23	$86M	—	$21M
Q4 23	$95M	$27M	—
Q1 24	$84M	$24M	—
Q2 24	$94M	$31M	—
Q3 24	$87M	$76M	—
Q4 24	$83M	$34M	—
Q1 25	$91M	$27M	—
Q2 25	$69M	$25M	—
Q3 25	$65M	$22M	—
Q4 25	$61M	$22M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$130M	$993M	$1.1B
Q2 23	$91M	$948M	$1.0B
Q3 23	$114M	$885M	$999M
Q4 23	$312M	$949M	$1.3B
Q1 24	$88M	$1.1B	$1.2B
Q2 24	$155M	$1.1B	$1.2B
Q3 24	$85M	$1.0B	$1.1B
Q4 24	$101M	$939M	$1.0B
Q1 25	$81M	$873M	$954M
Q2 25	$115M	$746M	$861M
Q3 25	$102M	$686M	$788M
Q4 25	$143M	$543M	$685M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	53M	+0.2%
Q2 23	53M	+0.2%
Q3 23	54M	+1.3%
Q4 23	61M	+12.9%
Q1 24	72M	+17.3%
Q2 24	72M	+0.3%
Q3 24	72M	+0.3%
Q4 24	72M	+0.0%
Q1 25	73M	+0.8%
Q2 25	73M	+0.4%
Q3 25	73M	-0.1%
Q4 25	65M	-11.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 16	—	—
FY 17	—	—
FY 18	$173K	83
FY 19	$323K	133
FY 20	$145K	179
FY 21	$191K	280
FY 22	$317K	415
FY 23	$176K	445
FY 24	$613K	430
FY 25	$1M	246